Catalent Escapes UCB’s Early Injunction Bid in Vimpat Patent Suit

A Kentucky federal judge refused to temporarily block Catalent Pharma Solutions LLC from making or using the anticonvulsant lacosamide, finding UCB Inc. likely can’t show Catalent infringes a patent on the chemical compound.

UCB had asked a judge in the U.S. District Court for the Eastern District of Kentucky for a preliminary injunction blocking Catalent from using lacosamide. The chemical compound is the active ingredient in UCB’s epilepsy treatment Vimpat.

The lawsuit came after Catalent imported hundreds of kilograms of the compound to its manufacturing facility in Kentucky. Catalent said it was helping another drug company pursue regulatory approval for ...